ClearPoint Neuro, Inc.
Close on Oct 19, 2026
- Market cap
- $276.63M
- P/E (TTM)
- –
- Dividend yield
- –
About ClearPoint Neuro
Surgical & Medical Instruments & Apparatus, SIC 3841
ClearPoint Neuro is a medical device company that develops and commercializes systems for minimally invasive brain surgeries and neurocritical care. The company operates two main segments: neurosurgical medical devices and biologics and drug delivery partnerships. Its core device products include the ClearPoint navigation platform with associated hardware, disposable instruments, and software, as well as the ClearPoint Prism laser therapy system and the IRRAflow fluid exchange system. In biologics and drug delivery, it provides preclinical consulting, study design, and testing services. Its clients comprise acute care hospitals, neurosurgeons, academic institutions, contract research organizations, and pharmaceutical and biotechnology companies.
The company conducts business in the United States and international markets, collaborating with more than sixty partner organizations across research and clinical programs. Its corporate headquarters and principal executive offices are located in Solana Beach, California.
Summary of the business section of ClearPoint Neuro's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ClearPoint Neuro, Inc.
- Founded
- 1998
- Headquarters
- Solana Beach, CA
- Address
- 120 S. Sierra Avenue, Suite 100 92075
- Phone
- (949) 900-6833
- Employees
- 172, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Cherry Bekaert LLP, Tampa, Florida
Stock & identifiers
- Ticker
- CLPT
- Exchange
- Nasdaq
- Shares outstanding
- 31M, Jul 27, 2026
- Public float
- $328.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-40 reverse, Aug 15, 2016; 1-for-40 reverse, Jul 27, 2016
- SEC CIK
- 1285550
- CUSIP
- 18507C103
- ISIN
- US18507C1036
- EIN
- 58-2394628
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joseph Burnett | CEO and President, Director | 322,108 |
| L. Jeremy Stigall | Chief Business Officer | 110,263 |
| Danilo D'Alessandro | Chief Financial Officer | 103,769 |
| Mazin Sabra | Chief Operating Officer | 67,343 |
| R. John Fletcher | Director | 131,011 |
| Timothy T. Richards | Director | 87,544 |
| Matthew B. Klein | Director | 46,935 |
| Linda M. Liau | Director | 64,801 |
| B. Kristine Johnson | Director | 71,116 |
| Lynnette C. Fallon | Director | 48,227 |
| Pascal E. R. Girin | Director | 110,623 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Burnett | $2.81M | $2.13M | $1.19M | $162 | – |
| FY2024 Mr. Burnett | $2.53M | $5.88M | $1.15M | $137 | – |
| FY2023 Mr. Burnett | $2.00M | $1.46M | $884.74K | $43 | – |
| FY2022 Mr. Burnett | $2.13M | $1.93M | $835.06K | $53 | – |
| FY2021 Mr. Burnett | $1.47M | $986.38K | $592.50K | $71 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 6, 2026, we had 172 full-time employees, including the 37 employees who joined us in connection with the IRRAS acquisition.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 20, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 19, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 11, 2020 | Name change | Name changed from MRI INTERVENTIONS, INC. to ClearPoint Neuro, Inc. |
| Dec 6, 2019 | Delisting | Notice of delisting from exchange (Form 25) |
| Dec 6, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 26, 2019 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 1, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jul 6, 2016 | Listing | Registration of securities on an exchange (Form 8-A) |
| Oct 22, 2010 | Name change | Name changed from SURGIVISION INC to MRI INTERVENTIONS, INC. |
| Jul 16, 2010 | Listing | Registration of securities on an exchange (Form 8-A) |